BUELACH, Switzerland,
23
May
2018
|
00:00
Europe/Amsterdam

BIOTRONIK Announces Further Investment into Magmaris, Its Unique Resorbable Magnesium Scaffold Program

New Clinical Data on Target Lesion Failure is Comparable to Second-Generation DES

Data presented during the EuroPCR congress on the Magmaris Resorbable Magnesium Scaffold (RMS) provide further evidence on its continued safety and efficacy, also in a more complex population.

Dr. Stefan Verheye, M.D., Ph.D., Senior Interventional Cardiologist at Antwerp Cardiovascular Institute, Antwerp, Belgium presented results on the first 200 patients from the cohort of 1,065 patients included in the BIOSOLVE-IV registry. The data show comparable target lesion failure (TLF) rates (4.6%) to second generation drug-eluting stents at 12 months and only one case of scaffold thrombosis (after DAPT interruption before the event). These promising outcomes included 14.5% of NSTEMI patients, a challenging patient group.

“The new data give insights in a more complex population and add to the body of evidence supporting the efficacy of Magmaris,” Dr. Michael Kang-Yin Lee, Honorary Clinical Associate Professor of the University of Hong Kong and Consultant Cardiologist at Queen Elizabeth Hospital, Hong Kong, China commented as Principal Investigator of the BIOSOLVE-IV study.

In addition, new optical coherence tomography data at three years from BIOSOLVE-II was presented by Dr. Michael Joner, Professor in Interventional Cardiology at the German Heart Center, Munich, Germany. The presented data confirmed earlier pre-clinical findings on Magmaris showing reduced signs of neoatherosclerosis, a possible complication of permanent implants.

“As more evidence of the benefits of magnesium as a scaffold material emerges, supported by the results of our ongoing clinical program, BIOTRONIK will further invest in resorbable magnesium technology,” said Dr. Alexander Uhl, Senior Vice President Corporate Marketing at BIOTRONIK. “This investment underlines our belief that the RMS has a significant role to play in interventional cardiology. We firmly expect that evidence will support the relevance of the RMS in wider indications and patient populations.”

About BIOTRONIK:

BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries.